Florida Cancer Specialists Presents Early Data on Novel Prostate, Urothelial Cancer Therapies
Event summary
- Florida Cancer Specialists (FCS) physicians presented initial findings from two clinical trials at the ASCO 2026 Genitourinary Cancers Symposium.
- One trial (Phase 1b) assessed the combination of pasritamig (PAS) and docetaxel (DOCE) for metastatic castration-resistant prostate cancer (mcrPC).
- The other trial (Phase 1/2) evaluated AVZO-103, a bispecific Nectin4/Trop2 antibody-drug conjugate (ADC), for urothelial cancer and other solid tumors.
- Manish Patel, MD, led the prostate cancer study, while Cesar Augusto Perez, MD, co-authored the urothelial cancer study.
- The findings underscore FCS’s commitment to clinical research and accelerating new treatment options.
The big picture
The presentation highlights the ongoing shift towards precision medicine and targeted therapies in genitourinary cancers, a market segment representing a significant portion of the overall cancer burden in the US. FCS’s focus on clinical trials positions it to capitalize on this trend, but also exposes it to the inherent risks associated with early-stage drug development and dependence on external research organizations. The data presented, while preliminary, could influence investment decisions and partnerships within the oncology space.
What we're watching
- Clinical Efficacy
- The initial Phase 1b results for pasritamig and docetaxel will be scrutinized for signs of meaningful clinical benefit in mcrPC, as this combination represents a potential new approach to a difficult-to-treat cancer.
- ADC Adoption
- The progress of AVZO-103, a bispecific ADC, will be watched closely, as the success of this therapy could validate the broader ADC approach in urothelial cancer and other solid tumors.
- Partner Reliance
- FCS’s continued reliance on partnerships like Sarah Cannon Research Institute will determine the breadth and depth of its clinical trial pipeline and ability to compete in the oncology research landscape.
Related topics